MADIT-CRT Results

MADIT-CRT provides clinical evidence that early intervention with CRT-D therapy reduces the relative risk of all-cause mortality or first heart failure event by 34% when compared to ICD therapy, significantly slowing the progression of the disease (p = 0.001).

• This benefit was driven by a 41% relative reduction in the risk of heart failure events in the CRT-D arm vs. the ICD arm (p < 0.001).

• The benefit in the CRT-D arm was similar for patients with ischemic and non-ischemic heart failure.

• The primary endpoint is further supported by an improvement in cardiac function — At just 12 months, CRT-D patients experienced a significant 11% improvement in LVEF as compared to a 3% improvement in ICD patients (p < 0.001) and experienced a greater reduction in left ventricular volumes than patients in the ICD arm.

MADIT-CRT Presented at European Society of Cardiology Congress
Access slides » presented by Principal Investigator Dr. Arthur J. Moss, Professor of Medicine, University of Rochester Medical Center

MADIT-CRT Published in the New England Journal of Medicine (NEJM)
View and print the NEJM article »

View All Press Releases »
View MADIT-CRT Trial Design »
Learn More About Cardiac Rhythm Management Clinical Trials »

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Information for the use only in countries with applicable health product registrations.